- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02025777
Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease (UC)
Study Hypothesis UC Disease affects the colon. PillCam IBD may be used for visualization of the colon mucosa in UC Disease patients. This study is designed to evaluate the yield and clinical impact of IBD capsule in detecting lesions associated with UC Disease and to determine the agreement between PillCam Platform with the IBD capsule and optical colonoscopy in the evaluation of UC disease extent.
Primary Scientific Objective To evaluate the agreement between PillCam IBD system and optical colonoscopy in the evaluation of UC disease extent (Non-active disease, Proctitis, Left-sided colitis, Pancolitis)
Proposed Design Established UC disease patients whose clinical condition suggests ongoing disease activity, aged 18 years and up, who have no evidence of symptomatic stricture or other obstruction that would prevent capsule passage will be enrolled in this study.
Patients will undergo bowel prep, followed by a PillCam IBD capsule examination and colonoscopy examination.
The Rapid videos will be evaluated by two readers, each from a different site, the colonoscopy videos will be evaluated by two other physicians, at the sites
INCLUSION CRITERIA
All subjects must fulfill all of the following inclusion criteria:
- Patients ages 18 years and up
- Patient has known UC according to physician discretion
Patient has at least one positive inflammatory marker from the following:
- ESR
- CRP
- CBC
- Patient is indicated and eligible for a standard of care colonoscopy examination
- Patient agrees to sign consent form
EXCLUSION CRITERIA
The presence of any of the following will exclude a patient from study enrollment:
- Crohn's Disease
- Antibiotic Associated Colitis
- Stool positive for O&P (C&S within 3 months of enrollment)
- Other known infectious cause of increased symptoms
- Known intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting.
- Definite long stricture seen on radiological exam.
- Non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or more) during the 4 weeks preceding enrollment
- Suspected GI stricture, followed by patency capsule study or other imaging study that could not prove patency of the GI tract.
- Patient has had prior abdominal surgery of the gastrointestinal tract in the last 6 months, other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Patient with known gastrointestinal motility disorders.
- Subjects with known or suspected delayed gastric emptying
- Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions.
- Patient has Type 1 or Type II Diabetes.
- Patient has any allergy or other known contraindication to the medications used in the study.
- Patient has any condition, which precludes compliance with study and/or device instructions.
- Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
- Concurrent participation in another clinical trial using any investigational drug or device.
- Patient suffers from a life threatening condition
- Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients ages 18 years and up
- Patient has known UC according to physician discretion
Patient has symptoms of fresh bleeding and/or bloody diarrhea and/or at least one positive inflammatory marker within the past three months from the following:
- ESR
- CRP
- CBC
- Patient is indicated and eligible for a standard of care colonoscopy examination for evaluation of disease activity and not for routine screening for dysplasia or colorectal cancer
- Patient agrees to sign consent form
Exclusion Criteria:
- Crohn's Disease
- Antibiotic Associated Colitis
- Stool positive for O&P and for C. difficile toxin within 3 months of enrollment
- Other known infectious cause of increased symptoms
- Known intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting.
- Definite tight or long stricture seen on radiological exam.
- Non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or more) during the 4 weeks preceding enrollment
- Suspected GI stricture, followed by patency capsule study or other imaging study that could not prove patency of the GI tract.
- Patient has had prior abdominal surgery of the gastrointestinal tract in the last 6 months, other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Patient with a known gastrointestinal motility disorder.
- Subjects with known or suspected delayed gastric emptying
- Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions.
- Patient has Type 1 or Type II Diabetes.
- Patient has any allergy or other known contraindication to the medications used in the study.
- Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
- Concurrent participation in another clinical trial using any investigational drug or device.
- Patient suffers from a life threatening condition
- Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: capsule endoscopy and colonoscopy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Agreement between PillCam IBD system and optical colonoscopy in the evaluation of UC disease extent (Non-active disease, Proctitis, Left-sided colitis, Pancolitis)
Time Frame: 3 weeks post capsule procedure
|
3 weeks post capsule procedure
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Agreement between PillCam IBD system and optical colonoscopy in the evaluation of UC disease activity based on the Mayo Score (non-active, mild, moderate, severe)
Time Frame: 3 weeks after capsule procedure
|
3 weeks after capsule procedure
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Type, incidence, severity, and duration of adverse events
Time Frame: 9 days after capsule procedure
|
9 days after capsule procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yago González Lama, Dr.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RD-210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Capsule Endoscopy
-
University Medical Center GroningenMaastricht University Medical Center; Erasmus Medical Center; Medtronic - MITG; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and other collaboratorsCompletedLynch Syndrome | Small Bowel NeoplasiaNetherlands
-
Capso Vision, Inc.Generic Devices Consulting, Inc.CompletedUlcer | Inflammatory Bowel Diseases | Celiac Disease | Crohn Disease | Intestinal DiseaseUnited States
-
Children's Mercy Hospital Kansas CityMedtronic - MITGCompleted
-
Fondazione Poliambulanza Istituto OspedalieroHospices Civils de Lyon; Fondazione Policlinico Universitario Agostino Gemelli... and other collaboratorsCompletedIron Deficiency Anemia | Obscure Gastrointestinal BleedingItaly
-
Technical University of MunichCompleted
-
Medtronic - MITGCompletedPerformance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)Celiac DiseaseUnited States, Italy, Finland
-
Brigham and Women's HospitalCompletedGastroesophageal Reflux Disease | Non-Cardiac Chest Pain
-
Taipei Medical University WanFang HospitalCompletedHealthy Patient on Good ConditionTaiwan
-
University of RochesterWithdrawn